ACLX Logo

Arcellx, Inc. (ACLX) 

NASDAQ$71.68
Market Cap
$3.94B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
422 of 924
Rank in Industry
246 of 527

ACLX Insider Trading Activity

ACLX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$74,870,56654100

Related Transactions

Ware Olivia Cdirector0$02$1.16M$-1.16M
Gilson MichelleCHIEF FINANCIAL OFFICER0$010$6.58M$-6.58M
Elghandour RamiSEE REMARKS0$06$8.56M$-8.56M
Patel Kavitadirector0$017$8.66M$-8.66M
Heery ChristopherCHIEF MEDICAL OFFICER0$018$14.34M$-14.34M
Carroll Jilldirector0$01$35.58M$-35.58M

About Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid â€¦

Insider Activity of Arcellx, Inc.

Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $74.87M worth of Arcellx, Inc. stock.

On average, over the past 5 years, insiders at Arcellx, Inc. have bought $91.25M and sold $68.36M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.

List of Insider Buy and Sell Transactions, Arcellx, Inc.

2025-02-26SaleElghandour RamiSEE REMARKS
38,300
0.0727%
$62.02$2.38M+11.06%
2025-02-25SalePatel Kavitadirector
1,500
0.0027%
$63.16$94,740+9.66%
2025-02-24SaleHeery ChristopherCHIEF MEDICAL OFFICER
10,155
0.0188%
$63.79$647,773+8.76%
2025-02-04SalePatel Kavitadirector
1,500
0.0028%
$64.57$96,855-3.09%
2025-01-14SalePatel Kavitadirector
1,500
0.0028%
$65.87$98,801+1.86%
2025-01-08SaleElghandour RamiSEE REMARKS
13,837
0.0259%
$73.69$1.02M-8.87%
2025-01-08SaleHeery ChristopherCHIEF MEDICAL OFFICER
3,553
0.0066%
$73.69$261,831-8.87%
2025-01-08SaleGilson MichelleCHIEF FINANCIAL OFFICER
3,997
0.0075%
$73.69$294,551-8.87%
2025-01-07SaleElghandour RamiSEE REMARKS
16,474
0.03%
$75.53$1.24M-14.54%
2025-01-07SaleHeery ChristopherCHIEF MEDICAL OFFICER
4,230
0.0077%
$75.53$319,485-14.54%
2025-01-07SaleGilson MichelleCHIEF FINANCIAL OFFICER
14,012
0.0255%
$75.68$1.06M-14.54%
2025-01-06SaleElghandour RamiSEE REMARKS
15,111
0.0287%
$77.17$1.17M-11.97%
2025-01-06SaleHeery ChristopherCHIEF MEDICAL OFFICER
2,975
0.0056%
$77.17$229,571-11.97%
2025-01-06SaleGilson MichelleCHIEF FINANCIAL OFFICER
5,621
0.0107%
$77.17$433,755-11.97%
2025-01-03SaleElghandour RamiSEE REMARKS
15,112
0.0284%
$79.55$1.2M-16.33%
2025-01-03SaleHeery ChristopherCHIEF MEDICAL OFFICER
2,975
0.0056%
$79.55$236,656-16.33%
2025-01-03SaleGilson MichelleCHIEF FINANCIAL OFFICER
5,622
0.0106%
$79.55$447,219-16.33%
2024-12-24SalePatel Kavitadirector
1,500
0.0028%
$76.97$115,451-13.75%
2024-12-03SalePatel Kavitadirector
1,500
0.0028%
$91.88$137,818-22.96%
2024-11-15SaleGilson MichelleCHIEF FINANCIAL OFFICER
1,761
0.003%
$88.87$156,508-19.48%
Total: 99
*Gray background shows transactions not older than one year

Insider Historical Profitability

29%
Carroll Jilldirector
1479148
2.6921%
$106.03M16+6.58%
New Enterprise Associates 15, L.P.10 percent owner
6745262
12.2766%
$483.5M20+40.21%
Novo Holdings A/S10 percent owner
4016878
7.3109%
$287.93M10+6.58%
SR ONE CAPITAL MANAGEMENT, LLC10 percent owner
1658780
3.019%
$118.9M11+6.58%
BASKETT FORESTdirector
0
0%
$011+73.84%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$52,263,649
70
1.18%
$4.36B
$140,165,669
33
85.24%
$3.32B
$11,859,102
17
18.62%
$5.25B
$74,605,681
14
47.06%
$3.61B
$57,686,748
13
21.11%
$4.3B

ACLX Institutional Investors: Active Positions

Increased Positions125+63.78%13M+26.37%
Decreased Positions83-42.35%4M-8.87%
New Positions50New8MNew
Sold Out Positions27Sold Out2MSold Out
Total Postitions238+21.43%58M+17.5%

ACLX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$515,749.0014.47%7.96M+1M+22.8%2024-12-31
Gilead Sciences, Inc.$435,642.0012.22%6.72M+7MNew2024-12-31
Paradigm Biocapital Advisors Lp$283,367.007.95%4.37M+371,601+9.29%2024-12-31
Blackrock, Inc.$249,818.007.01%3.85M-392,671-9.25%2024-12-31
Nea Management Company, Llc$242,768.006.81%3.75M00%2024-12-31
Perceptive Advisors Llc$225,502.006.33%3.48M-409,781-10.54%2024-12-31
Vanguard Group Inc$215,857.006.06%3.33M+867,996+35.25%2024-12-31
Ra Capital Management, L.P.$180,675.005.07%2.79M+935,848+50.55%2024-12-31
Sr One Capital Management, Lp$152,109.004.27%2.35M00%2024-12-31
Price T Rowe Associates Inc /Md/$137,504.003.86%2.12M+220,711+11.61%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1.68SellsBuysStrong BuyBuyHoldSellStrong SellACLXHighAverageLowSeries 4